When You Need a Hands-on Partner for Your Pain Trials
//
Clinical Research Solutions
We support pharmaceutical, biotech, and medical device sponsors conducting pain studies across diverse modalities, including small molecules, biologics, regenerative therapies, and drug-device combinations.
Developing and operationalizing pain trials requires precision, therapeutic depth, and the ability to manage regulatory and operational complexity—especially in placebo-sensitive and controlled-substance settings. With over 20 years of experience, PRC Clinical delivers full-service and niche support for pain programs across all phases, from First-in-Human through Phase 3.
PRC Clinical is the right CRO for small-to-mid-size pain studies requiring experienced, high-touch execution.
Key Stats and Scope
PRC Clinical supports First-in-Human through Phase 3 trials, offering both full-service delivery and modular, niche services tailored to the needs of each program.
PRC Clinical’s Pain Trial Footprint Includes:
Types of Pain Addressed
Acute Pain
- Post-operative models (e.g., bunionectomy, shoulder surgery)
- Hospital-based acute pain interventions
Chronic Pain
- Lower back pain
- Shoulder pain
- Cancer-related pain
Neuropathic Pain
- Diabetic neuropathy
- HIV-associated neuropathy
- Post-herpetic neuralgia
- Chemotherapy-induced peripheral neuropathy (CIPN)
Rare Pain Conditions
- Neuro-oncologic pain syndromes
- Complex regional pain disorders
Delivery & Formulation Expertise
- Oral formulations
- Intravenous (IV)
- Intrathecal administration
- Intradiscal injections
- Spinal delivery
- Topical or transdermal delivery models
We Support a Full Range of Modalities:
- Opioids (Schedule II)
- Non-opioid small molecules (including NMDA modulators)
- Capsaicin-based topical and injectable agents
- Venom-derived peptide analgesics
- Biologics and monoclonal antibodies
- Regenerative medicine: autologous & allogeneic stem cell therapies
- Adjunct and supportive therapies (e.g., rescue medications)
Therapeutic & Regulatory Infrastructure
- DEA-controlled substance trial support
- Protocols with rescue medication and blinding requirements
- Pain scoring methodologies including VAS, NPRS, BPI, McGill Pain Questionnaire, and WOMAC where applicable
- Full-site support including ePRO/patient diaries and adverse event management
What Sets PRC Clinical Apart
Experience Across Acute and Chronic Pain
PRC has successfully delivered studies involving both short-duration surgical pain and long-duration chronic or neuropathic indications. We bring consistency, continuity, and senior oversight across all trial phases.
Innovative Pain Therapeutics
Our portfolio includes trials using venom-derived peptides, stem cell-based regenerative approaches, and repurposed central-acting agents—each requiring tailored operational frameworks.
Controlled Substance and DEA Expertise
We’ve led trials involving Schedule II agents and novel analgesics requiring secure drug management, site-level DEA training, and regulatory coordination.
Pain-Specific Tools and Methods
We have deep expertise implementing validated pain measurement tools including Visual Analog Scale (VAS), Numeric Pain Rating Scale (NPRS), Brief Pain Inventory (BPI), McGill Pain Questionnaire, and WOMAC. PRC also manages electronic diary workflows and placebo response mitigation strategies with high precision.
Selected Case Experience
Stem Cell Therapy for Chronic Low Back Pain (Intradiscal Injection):
PRC led clinical operations for both autologous and allogeneic stem cell therapy programs targeting chronic low back pain. Our team oversaw site engagement, enrollment acceleration, and product accountability—ensuring compliant delivery of intradiscal injections and real-time oversight of safety reporting workflows.
Peptide-Based Analgesic Program (Intrathecal Delivery):
PRC managed U.S. operations for a post-approval safety program of a venom-derived non-opioid analgesic delivered intrathecally for treatment-refractory pain. We coordinated protocol compliance, DEA controls, and site training for specialized surgical administration.
Centrally Acting Non-Opioid Analgesic (Neuropathic Cancer Pain):
PRC oversaw multi-site trial operations for a repurposed non-opioid agent targeting NMDA pathways in cancer-related neuropathy. Our team managed complex safety oversight, rescue medication integration, and high-risk patient populations.
HIV and Diabetic Neuropathy Trials
Delivered full-service support for trials targeting HIV-associated and diabetic neuropathic pain, including regulatory strategy, site management, and robust patient diary workflows across geographically diverse sites.
Surgical Pain Models (Bunionectomy and Lower Back Pain):
Conducted randomized trials using validated post-operative pain models (e.g., bunionectomy, spinal surgery) for dose-ranging and early efficacy assessments. PRC oversaw pain scoring instrument integration, electronic diary setup, and rescue medication compliance across multiple U.S. sites to ensure data quality and protocol adherence.
Our team has a strong track record of meeting enrollment targets in pain studies, including complex protocols involving controlled substances or surgical recovery models. We tailor our recruitment strategies to the indication, combining digital outreach, site engagement tools, and targeted patient messaging to support reliable enrollment—even in high-screen-failure or placebo-sensitive indications.
Whether you require full-service delivery or focused support for feasibility, monitoring, site engagement, or regulatory oversight, our flexible model ensures the right resourcing for your study’s scale and complexity.
Whether your trial involves traditional analgesics, biologics, stem cell therapies, or novel pain-modulating mechanisms, PRC Clinical is built to deliver small-to-mid-size pain studies with speed, clarity, and senior-level attention.
